Supplementary Figure 12 from SPP1+ Tumor-Associated Macrophages Drive Immunotherapy Resistance via CD8+ T-cell Dysfunction in Clear-Cell Renal Cell Carcinoma

Key Points

• SPP1+ tumor-associated macrophages drive immunotherapy resistance by impairing CD8 T-cell function, affecting treatment outcomes.
• The study identified specific dysfunction in CD8 T-cells associated with SPP1+ TAMs, providing insights into cancer therapy challenges.
• Utilizing flow cytometry, the research characterized SPP1+ TAMs to uncover their impact on immune response in tumors.
• These findings highlight the need for targeted therapies that overcome macrophage-driven immunotherapy resistance.

Abstract